Analysts on Wall Street project that Becton Dickinson (BDX - Free Report) will announce quarterly earnings of $2.96 per share in its forthcoming report, representing an increase of 3.5% year over year. Revenues are projected to reach $5.03 billion, increasing 4.3% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Becton Dickinson metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- BD Interventional' should come in at $1.23 billion. The estimate points to a change of +4.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- BD Interventional- Surgery' should arrive at $377.86 million. The estimate suggests a change of -0.8% year over year.
The consensus among analysts is that 'Revenues- BD Interventional- Peripheral Intervention' will reach $496.29 million. The estimate suggests a change of +6% year over year.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional- Urology and Critical Care' of $359.96 million. The estimate indicates a change of +7.1% from the prior-year quarter.
Analysts forecast 'Revenues- BD Medical- Medication Management Solutions- International' to reach $177.04 million. The estimate points to a change of +2.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- BD Life Sciences- Biosciences- International' at $238.98 million. The estimate indicates a year-over-year change of +4.8%.
Analysts' assessment points toward 'Revenues- BD Interventional- Peripheral Intervention- United States' reaching $266.52 million. The estimate indicates a year-over-year change of +4.1%.
Analysts predict that the 'Revenues- BD Interventional- Urology and Critical Care- United States' will reach $285.10 million. The estimate indicates a year-over-year change of +8.4%.
It is projected by analysts that the 'Revenues- BD Interventional- United States' will reach $835.07 million. The estimate indicates a year-over-year change of +2.7%.
The consensus estimate for 'Revenues- BD Interventional- Surgery- International' stands at $88.29 million. The estimate points to a change of +2.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- BD Interventional- Peripheral Intervention- International' will likely reach $228.40 million. The estimate suggests a change of +7.2% year over year.
Analysts expect 'Revenues- BD Interventional- Urology and Critical Care- International' to come in at $76.41 million. The estimate indicates a change of +3.3% from the prior-year quarter.
View all Key Company Metrics for Becton Dickinson here>>>
Shares of Becton Dickinson have demonstrated returns of -6.4% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #2 (Buy), BDX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Analysts on Wall Street project that Becton Dickinson (BDX - Free Report) will announce quarterly earnings of $2.96 per share in its forthcoming report, representing an increase of 3.5% year over year. Revenues are projected to reach $5.03 billion, increasing 4.3% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Becton Dickinson metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- BD Interventional' should come in at $1.23 billion. The estimate points to a change of +4.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- BD Interventional- Surgery' should arrive at $377.86 million. The estimate suggests a change of -0.8% year over year.
The consensus among analysts is that 'Revenues- BD Interventional- Peripheral Intervention' will reach $496.29 million. The estimate suggests a change of +6% year over year.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional- Urology and Critical Care' of $359.96 million. The estimate indicates a change of +7.1% from the prior-year quarter.
Analysts forecast 'Revenues- BD Medical- Medication Management Solutions- International' to reach $177.04 million. The estimate points to a change of +2.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- BD Life Sciences- Biosciences- International' at $238.98 million. The estimate indicates a year-over-year change of +4.8%.
Analysts' assessment points toward 'Revenues- BD Interventional- Peripheral Intervention- United States' reaching $266.52 million. The estimate indicates a year-over-year change of +4.1%.
Analysts predict that the 'Revenues- BD Interventional- Urology and Critical Care- United States' will reach $285.10 million. The estimate indicates a year-over-year change of +8.4%.
It is projected by analysts that the 'Revenues- BD Interventional- United States' will reach $835.07 million. The estimate indicates a year-over-year change of +2.7%.
The consensus estimate for 'Revenues- BD Interventional- Surgery- International' stands at $88.29 million. The estimate points to a change of +2.7% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- BD Interventional- Peripheral Intervention- International' will likely reach $228.40 million. The estimate suggests a change of +7.2% year over year.
Analysts expect 'Revenues- BD Interventional- Urology and Critical Care- International' to come in at $76.41 million. The estimate indicates a change of +3.3% from the prior-year quarter.
View all Key Company Metrics for Becton Dickinson here>>>
Shares of Becton Dickinson have demonstrated returns of -6.4% over the past month compared to the Zacks S&P 500 composite's -2% change. With a Zacks Rank #2 (Buy), BDX is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Get the latest research report on BDX - FREE